Squamous cell carcinoma is abbreviated as squamous cell carcinoma, also known as epidermal carcinoma. It is a malignant tumor that occurs in epidermal or accessory organ cells. Cancer cells have different degrees of keratinization. More common in areas covered by squamous epithelium, such as skin, mouth, lips, esophagus, cervix, vagina, etc., can form squamous cell carcinoma through metaplasia of squamous epithelium. We understand squamous cell carcinoma, so what is the first-line chemotherapy for squamous cell carcinoma?

　　Stage I to IIIA non-small cell lung cancer (NSCLC) is mainly treated with surgery. Chemotherapy is generally used as postoperative adjuvant therapy, and can also be used as preoperative neoadjuvant chemotherapy for patients with stage IIIA.

　　Patients in stage Ⅴ are mainly treated with chemotherapy and can receive local palliative radiotherapy. Although there are many effective chemotherapy options for non-small cell lung cancer (NSCLC), the overall efficacy is not as good as for small cell lung cancer (SCLC). The effective rate is generally 20% to 40%. It has been reported that increasing the dose can increase the intensity to about 50%, but most of them require hematopoietic stimulating factor treatment.

　　Non-small cell lung cancer (NSCLC) chemotherapy can achieve complete remission in very few patients, so the vast majority cannot be cured by chemotherapy. Need to cooperate with other treatment methods such as surgery or radiotherapy.

　　Small cell lung cancer (SCLC) can improve the survival period through radiotherapy, chemotherapy and surgical comprehensive treatment in a limited period, and chemotherapy is the mainstay in a wide period, and the prognosis is very poor.